On April 5, 2024, Melissa Epperly resigned as Chief Financial Officer of Zentalis Pharmaceuticals, Inc. (Zentalis), effective immediately. Effective on the Transition Date, the Company's Board of Directors (the Board") appointed the Company's President, Cam Gallagher, as interim Chief Financial Officer. Mr. Gallagher, age 54, has served as the Company's President since May 2022 and as a member of the Board since the Company's founding in December 2014.

Mr. Gallagher served as the Chief Business Officer at Immusoft Corp. (Immusoft), a preclinical gene therapy company, from April 2018 to May 2022, and as a member of Immusoft's Board of Directors from December 2022 to March 2024. From October 2016 to June 2019, Mr. Gallagher served as the Head of Corporate Development and as a member of the Board of Directors of Oncternal Therapeutics, Inc. and from 2014 to 2016, he served as the Chief Business Officer and as a member of the Board of Directors of RetroSense Therapeutics, LLC, a gene therapy company, until its acquisition by Allergan plc.

Mr. Gallagher also served as the Chief Business Officer of Kalyra Pharmaceuticals, Inc. from July 2013 to January 2024. Mr. Gallagher has been a member of the Board of Directors of Ocuphire Pharma, Inc., a clinical stage ophthalmology company, since November 2020 and currently serves as Chairman of the Board of Directors. Mr. Gallagher has also served as a member of the Board of Directors of Healios K.K. from March 2022 to March 2023, as a member of the Board of Directors of selectION, Inc. since July 2018, as a managing member of Recurium IP Holdings, LLC (Recurium IP) since October 2017, and as managing director of Nerveda, LLC, a life science seed fund he co-founded, since September 2007.

He also served as a member of the Board of Directors of Ray Therapeutics, Inc., a biotechnology company specializing in optogenetics gene therapies, from February 2021 to May 2023, and as a member of the Board of Directors of VelosBio Inc., an oncology-focused biopharmaceutical company, from December 2017 until its acquisition by Merck & Co., Inc. in December 2020. In addition, Mr. Gallagher has served on the Board of the Moores Cancer Center at UC San Diego Health since May 2019. Mr. Gallagher received an M.B.A. from the University of San Diego and a B.S. in Business Administration from Ohio University.

There is no arrangement or understanding between Mr. Gallagher and any other person, pursuant to which Mr. Gallagher was selected as interim Chief Financial Officer, Treasurer and principal financial officer.